image description

Tag: Kenneth Farber

LRA’s Virtual Annual Conference Brings Together Top Lupus Researchers for Dynamic Scientific Exchange

October 28, 2021 Two-day meeting focuses on sharing latest news and generating new scientific ideas  The Lupus Research Alliance (LRA) held our annual scientific conference, the Forum for Discovery, online for a second year given the continued concerns during the COVID-19 pandemic. The virtual capability allowed more than 150 funded investigators, scientific advisors, and partners […] Read More

Important Message from CEO Kenneth Farber: U.S. FDA Approves New Lupus Treatment

August 2, 2021 Dear Friend of the Lupus Research Alliance, As we reported this morning, the lupus community has much to celebrate with the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (brand name, Saphnelo™). As a first-in-class and only new treatment for systemic lupus erythematosus in a decade, this approval marks a major […] Read More

LRA is Unraveling Lupus Heterogeneity to Turn Complexity to Cure

July 22, 2021 Why is lupus so tough to treat? Why is it so difficult to test possible new treatments in a clinical trial? Why are so many people needed for a clinical trial to prove effectiveness? And how does LRA intend to Turn Lupus Complexity to Cure? The answers lie at the core of […] Read More

Lupus Research Alliance Sets Bold New Strategic Plan for Research to Accelerate Innovative Research and Treatment Breakthroughs

Updated July 15, 2021 The Lupus Research Alliance (LRA) today announced a bold Strategic Plan for Research (Strategic Plan) that identifies core issues and sets new priorities to transform lupus research, accelerate breakthrough treatments and ultimately, find a cure through the power of precision medicine. The Strategic Plan is informed by years of funded research […] Read More

LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020

30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […] Read More

Vaccines and Lupus: What to Know Amid COVID-19

January 14, 2021 LRA’s President and CEO Kenneth Farber taped this video series – Vaccines and Lupus: What to Know Amid COVID-19 – to explain what vaccines do, how the new COVID-19 vaccine technologies work, and what the LRA is doing to address questions on the safety of these new vaccines for people with lupus. […] Read More

Third Vaccine Shield Against COVID-19 Rolling Out March 1, 2021

March 1, 2021 Americans gained a third weapon against COVID-19 this weekend with the availability of a third vaccine. On February 27, 2021, the U.S. Food and Drug Administration granted Emergency Use Authorization to the new vaccine from Janssen Pharmaceutical Companies of Johnson & Johnson to prevent COVID-19 in adults age 18 and older. The […] Read More

LRA Proudly Congratulates Dr. Lindsey Criswell on NIAMS Appointment

August 13, 2020 The Lupus Research Alliance is proud to congratulate one of our funded researchers, Lindsey A. Criswell, MD, MPH, DSc, on her new appointment as Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Currently Vice Chancellor of Research at the University of California, San Francisco, Dr. Criswell has […] Read More

Help Kick Off the ManyOne Can. Walk with Us to Cure Lupus

July 30, 2020 Click here to view the replay of our recent  Kickoff to the 2020 ManyOne Can Walk with Us to Cure Lupus presented by GSK.  Hosted by Lupus Research Alliance’s President Ken Farber, this FUNd-raising Zoom webcast featured seasoned Walk Captains who gave lots of great ideas for team building and FUNdraising, in […] Read More